The choice and duration of antiplatelet therapy in NSTE-ACS undergoing PCI is complex and is a hotly debated topic – particularly amongst patients at high bleeding risk. To gain insight into the real-world practices of a global cross-section of cardiologists, Radcliffe Medical Education, in partnership with the International Society of Cardiovascular Pharmacotherapy (ISCP), undertook a novel crowdsourcing project to capture their prevailing beliefs and practices in antiplatelet treatment, in patients at high bleeding risk.
We reported our findings in a paper recently published in the International Journal of Cardiology and are delighted to now bring you a roundtable discussion, featuring members of the steering committee, to further explain the project, the main findings, and the potential implications for future research.
To view the webinar please click here
To view the article please click here
This project was made possible by an unrestricted educational grant from AstraZeneca.